JWH-371
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a
synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 42 ± 1nM) and CB2 (Ki = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB1 receptor than the CB2 receptor. JWH-371 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]
Legality
In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.[2][3][4][5]
In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.[citation needed]
In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.[citation needed]
See also
- List of JWH cannabinoids
- Synthetic cannabinoid
References
- PMID 16889960.
- ^ : Schedules of controlled substances
- ^ "The 2020 Florida Statutes". www.leg.state.fl.us. Retrieved 20 August 2021.
- ^ "Arizona Revised Statutes Title 13. Criminal Code § 13-3401". www.azleg.gov. Retrieved 20 August 2021.
- ^ "California Code, Health and Safety Code - HSC § 11357.5". Findlaw.